raloxifene hydrochloride has been researched along with Weight Gain in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (50.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ilhan, N; Ozercan, IH; Susam, S; Tatar, O | 1 |
| Best, KL; Counts, DF; Goode, RL; Hoover, DM; Jones, CD; Merriman, RL; Neubauer, BL; Sarosdy, MF; Shaar, CJ; Tanzer, LR | 1 |
| Bjarnason, NH; Byrjalsen, I; Christiansen, C; Haarbo, J; Kauffman, RF | 1 |
| Blau, R; Lower, EE; Rohatgi, N | 1 |
4 other study(ies) available for raloxifene hydrochloride and Weight Gain
| Article | Year |
|---|---|
Is there any potential anticancer effect of raloxifene and fluoxetine on DMBA-induced rat breast cancer?
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Antineoplastic Agents; Body Weight; Carcinogens; Enzyme-Linked Immunosorbent Assay; Female; Fluoxetine; Mammary Neoplasms, Experimental; Raloxifene Hydrochloride; Rats; Rats, Wistar; Weight Gain | 2019 |
Raloxifene (LY156758) produces antimetastatic responses and extends survival in the PAIII rat prostatic adenocarcinoma model.
Topics: Adenocarcinoma; Adrenal Glands; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Disease Models, Animal; Dose-Response Relationship, Drug; Estradiol; Estrogen Antagonists; Fluorouracil; Incidence; Lung Neoplasms; Lymphatic Metastasis; Male; Organ Size; Piperidines; Prostate; Prostatic Neoplasms; Raloxifene Hydrochloride; Random Allocation; Rats; Rats, Wistar; Survival Rate; Testis; Weight Gain | 1995 |
Raloxifene inhibits aortic accumulation of cholesterol in ovariectomized, cholesterol-fed rabbits.
Topics: Animals; Aorta, Thoracic; Arteriosclerosis; Cholesterol; Cholesterol, Dietary; Disease Models, Animal; Estrogen Antagonists; Female; Organ Size; Ovariectomy; Piperidines; Rabbits; Raloxifene Hydrochloride; Uterus; Weight Gain | 1997 |
Raloxifene is associated with less side effects than tamoxifen in women with early breast cancer: a questionnaire study from one physician's practice.
Topics: Adult; Aged; Aged, 80 and over; Breast Neoplasms; Estrogen Antagonists; Female; Hot Flashes; Humans; Libido; Middle Aged; Neoplasms, Hormone-Dependent; Raloxifene Hydrochloride; Retrospective Studies; Selective Estrogen Receptor Modulators; Surveys and Questionnaires; Tamoxifen; Time Factors; Vaginal Discharge; Weight Gain | 2002 |